ALBUQUERQUE, N.M., October 7, 2015 – PaizaBio, a contract manufacturing organization (CMO) that provides Western pharmaceutical companies with rapid access to China’s rapidly growing sterile injectables market, will debut next week at CPhI Worldwide in Madrid, Spain, which runs October 12-14.
CPhI Worldwide is the pharmaceutical industry’s largest trade show, with more than 2,500 exhibitors and 36,000 attendees from over 150 countries. CPhI Worldwide is considered to be the most effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
U.S.-based PaizaBio was founded by Stuart Rose, a 40-year pharmaceutical industry veteran who spent the majority of his career in manufacturing and logistics in international markets. Most recently, he founded and sold OsoBio, an aseptic CMO headquartered in the United States. Rose’s new company, PaizaBio, differs in that its manufacturing operations are in China and focused on producing sterile injectables for China’s 1.4 billion citizens. China represents the largest market potential for global pharma today.
PaizaBio’s strategic partner in China is Ausia BioTech, a leading aseptic CMO for more than two decades in Hangzhou, located outside of Shanghai. Ausia BioTech operates a state-of-the-art, 40,000-square-meter facility that includes aseptic fill-and-finish, lyophilization, laboratories, packaging, and climate-controlled warehouse. Annual capacity is more than 300 million units (vials, cartridges, syringes).
Among the highlights of CPhI Worldwide are more than 100 free industry seminars, covering every sector. PaizaBio is sponsoring two informational discussions: , BAO-Gong®, the industry’s most comprehensive real-time remote manufacturing monitoring system, and the Trans-Pacific Aseptic Institute of Training (TPA-IT™), a sterile university in China dedicated to educating the sophisticated workforce demanded by aseptic processing.
Visit PaizaBio at CPhI in Hall 3 #3D104 or at www.PaizaBio.com